Celltrion Progresses COVID-19 Antibody Therapeutic, Pricing Will Be Key
Executive Summary
Celltrion presses ahead with Phase I study of COVID-19 antibody therapeutic, encouraged by the support of the South Korean government. The firm also urges global cooperation to lower prices of COVID-19 drugs and vaccines to end the global pandemic.
You may also be interested in...
Korea Seeks Two-Track Strategy For COVID-19 Drugs, Vaccines
As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.
Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral
Moderna maintains its lightning pace, but questions about its Phase III trial design remain.
Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change
Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.